sars-cov-2 infection; sars-cov-2 infection; this is a spontaneous report received from a contactable consumer from the regulatory authority. a 75 year-old male patient received bnt162b2 (comirnaty), administration date 12nov2021 (lot number: fh4751) as dose 3 (booster), single for covid-19 immunisation; covid-19 vaccine (covid-19 vaccine) (batch/lot number: unknown) as dose 2, single and (batch/lot number: unknown) as dose 1, single for covid-19 immunisation. relevant medical history included: "blood pressure high" (unspecified if ongoing). it was unsure if patient had had symptoms associated with covid-19 and the patient had not had a covid-19 test. patient was not enrolled in clinical trial. concomitant medications included: amlodipine, start date: 2018; indapamide, start date: 2019; influenza virus taken for immunisation, administration date 04oct2021; losartan taken for hypertension, start date: apr2012; oxybutynin, start date: 2012; paracetamol. the following information was reported: drug ineffective (medically significant), suspected covid-19 (medically significant) all with onset 15feb2022, outcome "recovering" and all described as "sars-cov-2 infection". no follow-up attempts are possible. no further information is expected.; sender's comments: linked report(s) : gb-pfizer inc-202200315544 same reporter/patient/vaccine, different events